Cancer Gene Therapy Past Achievements and Future Challenges
With the coming of the new millennium we are witnessing a revolution in our understanding of cancer genetics. These are very exciting times. Today we have at our disposal the technology to diagnose abnormalities in our cancer genes and the means to correc
- PDF / 17,495,733 Bytes
- 480 Pages / 468 x 720 pts Page_size
- 31 Downloads / 264 Views
ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY Editorial Board: NATHAN BACK, State University of New York at Buffalo IRUN R. COHEN, The Weizmann Institute of Science DAVID KRITCHEVSKY, Wistar Institute ABEL LAJTHA, N. S. Kline Institute for Psychiatric Research RODOLFO PAOLETTI, University of Milan Recent Volumes in this Series Volume 465 CANCER GENE THERAPY: Past Achievements and Future Challenges Edited by Nagy A. Habib Volume 466 CURRENT VIEWS OF FATTY ACID OXIDATION AND KETOGENESIS: From Organelles to Point Mutations Edited by Patti A. Quant and Simon Eaton Volume 467 TRYPTOPHAN, SEROTONIN, AND MELATONIN: Basic Aspects and Applications Edited by Gerald Huether, Walter Kochen, Thomas J. Simat, and Hans Steinhart Volume 468 THE FUNCTIONAL ROLES OF GLIAL CELLS IN HEALTH AND DISEASE: Dialogue between Glia and Neurons Edited by Rebecca Matsas and Marco Tsacopoulos Volume 469 EICOSANOIDS AND OTHER BIOACTIVE LIPIDS IN CANCER, INFLAMMATION, AND RADIATION INJURY, 4 Edited by Kenneth V. Honn, Lawrence J. Marnett, and Santosh Nigam Volume 470 COLON CANCER PREVENTION: Dietary Modulation of Cellular and Molecular Mechanisms Edited under the Auspices of the American Institute for Cancer Research Volume 471 OXYGEN TRANSPORT TO TISSUE XXI Edited by Andras Eke and David T. Delpy Volume 472 ADVANCES IN NUTRITION AND CANCER 2 Edited by Vincenzo Zappia, Fulvio Delia Ragione, Alfonso Barbarisi, Gian Luigi Russo, and Rossano Dello Iacovo Volume 473 MECHANISMS IN THE PATHOGENESIS OF ENTERIC DISEASES 2 Edited by Prem S. Paul and David H. Francis Volume 474 HYPOXIA: INTO THE NEXT MILLENNIUM Edited by Robert C. Roach, Peter D. Wagner, and Peter H. Hackett
A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.
CANCER GENE THERAPY Past Achievements and Future Challenges Edited by
Nagy A. Habib Imperial College School of Medicine
Hammersmith Hospital London, United Kingdom
KLUWER ACADEMIC PUBLISHERS NEW YORK, BOSTON, DORDRECHT, LONDON, MOSCOW
H%RRN ,6%1 3ULQW,6%1
174 1919
.OXZHU$FDGHPLF3XEOLVKHUV 1HZ50% and inhibited growth in diverse cancers in comparison with untreated cells or those infected with the virus vector lacking the mda-7 gene (Ad.vec) (Figs. 6 and 7) (Su et al., 1998b). To assess the infection efficiency of the virus, a parallel set of cultures were infected with 100pfu/cell of virus (Su et al., 1998b, 1998c). The viral infection efficiency in cultures ranged between 92-100% (unpublished data). Therefore, the growth inhibition and reduction in colony formation in cancer cells is a direct consequence of expression of the mda-7 transgene. In stark contrast, no discernable effect was evident in normal human mammary epithelial, human skin fibroblast or an immortalized (SV40 containing) human breast epithelial cell line (HBL-100) infected with 100pfu/cell of Ad.mda-7 S, even though replicate cultures inf
Data Loading...
